Summary:
Experimental data and early phase I/II studies suggest that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) can arrest progression of severe autoimmune diseases. We have evaluated the toxicity and disease response in 473 patients with severe autoimmune disease treated with autologous HSCT between 1995 and 2003, from 110 centers participating in the European Group for Blood and Marrow Transplantation (EBMT) autoimmune disease working party database. Survival, transplant-related mortality, treatment response and disease progression were assessed. In all, 420 patients (89%; 8674% at 3 years, median follow-up 20 months) were alive, 53 (11%) had died from transplant-related mortality (N ¼ 31; 773% at 3 years) or disease progression (N ¼ 22; 974% at 3 years). Of 370 patients, 299 evaluable for response (81%) showed a treatment response, which was sustained in 213 (71% of responders). Response was associated with disease (Po0.001), was better in patients who received cyclophosphamide during mobilization (relative risk (RR)3.28 (1.57-6.83)) and was worse with increasing age (440 years, RR0.29 (0.11-0.82)). Disease progression was associated with disease (Po0.001) and conditioning intensity (high intensity, RR1; intermediate intensity, RR1 .81 (0.96-3.42)); low intensity, RR2.34 (1.074-5.11) Autoimmune diseases represent a heterogeneous group of disorders with genetic, environmental and individual etiological factors. 1 Immunosuppression and immunomodulation are basic therapeutic strategies in all of them and are generally employed with success. Nonetheless, patients who do not respond, who require more toxic drugs to achieve or maintain remissions or who relapse despite continuing therapy present a therapeutic challenge.
Clinical response in some patients with autoimmune diseases who received hematopoietic stem cell transplantation (HSCT) for conventional indications, 2, 3 animal models with HSCT for prevention and treatment of severe autoimmune diseases 4, 5 and theoretical considerations all suggest that high-dose chemotherapy followed by hematopoietic stem cell rescue could 'reset' altered immunity. 6 Autologous HSCT could be a viable option. This led to an international collaboration and to a concept statement of the European Group for Blood and Marrow Transplantation (EBMT) and the European League against Rheumatism (EULAR) in 1995 7 to coordinate phase I/II trials and to gather collective experience.
Feasibility was soon documented. 8 Standard transplantation techniques, for example, stem cell mobilization, harvesting, graft engineering and conditioning proved to be applicable to these new indications. Toxicity of the procedure was shown to be comparable with results achieved in autologous HSCT for advanced malignancies. 9 Pilot series have established and defined response criteria. [10] [11] [12] [13] [14] [15] Insufficient data were as yet available to assess factors associated with outcome; mechanisms of action remained hypothetical. The present analysis documents the feasibility and efficacy of the procedure, clarifies the role of dose intensification and forms the basis for the ongoing prospective randomized phase III trials.
Patients and methods

Study design
This retrospective analysis is based on the concept statement of EBMT/EULAR in 1995. The basic principles include disease categories, patient selection, mobilization, in vitro manipulation, conditioning and treatment. 8 Briefly, patients should have a prognosis severe enough to justify the risk, but not be in such a condition as to be beyond salvage. Standard techniques, as used in HSCT for hematological malignancies, should be employed.
Data were collected by questionnaire or the electronic EBMT data management system ProMISe and updated annually. Participating centers (listed in Appendix A1) were requested to report all consecutive transplants and are subject to a random audit process (www.ebmt.org). They were requested to have their protocols approved by an ethics committee and to ask for written informed consent from their patients before HSCT.
Patients and disease categories
From 1995 to July 2003, 473 patients, 64% female, between 2 and 69 years of age (median 34 years) were reported (Table 1) . In all, 110 institutions from 21 countries participated. Patients with mobilization data only (N ¼ 11) were not included. Data on such patients were collected only initially; follow-up is incomplete. Data on potential complications with mobilized patients were published earlier. 10 Patients with second transplants (N ¼ 4) were also not included. Data were analyzed as of October 31, 2003 with a median follow-up of 20 months (range, 1-81 months).
Rheumatological (60%) and neurological (33%) autoimmune diseases represent the major disease categories. Substantial numbers of patients, allowing meaningful analysis of factors associated with outcome, were available for multiple sclerosis (N ¼ 150), systemic sclerosis (N ¼ 71), rheumatoid arthritis (N ¼ 70), juvenile idiopathic arthritis (N ¼ 51), systemic lupus erythematosus (N ¼ 62) and immune thrombocytopenia (N ¼ 10).
Definitions
Transplantation techniques (Table 2) . Stem cell source was categorized into bone marrow (54 patients; 11%) or peripheral blood stem cells (419 patients; 89%), which did include a few patients (N ¼ 4) with both stem cell products. Mobilization was subgrouped into mobilization with growth factor (granulocyte colony-stimulating factor, G-CSF, or granulocyte-macrophage colony stimulating factor, GM-CSF) alone (N ¼ 89;21%) and growth factor combined with cyclophosphamide or other chemotherapy (N ¼ 289; 69%).
Five main different conditioning regimens were employed, of which four were cyclophosphamide based. They were subgrouped arbitrarily but based on experience from HSCT in hematological malignancies, into high-, intermediate-or low-intensity regimens. 16 High-intensity regimens (17%) included busulfan plus cyclophosphamide7 antithymocyte globulin and any regimen including radiation; low-intensity (31%) was restricted to cyclophosphamide alone, melphalan alone and fludarabine-based regimens. All other conditioning regimens, including BEAM combination chemotherapy (BCNU, etoposide cytosine arabinoside and melphalan)7antithymocyte globulin, were considered as intermediate-intensity (52%) conditioning regimens.
Graft manipulation and T-/B-cell depletion (Table 2) . Graft manipulation and T-/B-cell depletion were grouped into four categories: none (14%), in vitro (29%), in vivo (20%) or both (37%). In the 'none' group, patients neither received antibodies during their conditioning nor their graft was manipulated. In the in vivo group, patients received mono-or polyclonal T-/B-cell antibodies during their conditioning. In the in vitro group, patients received CD34 selected grafts, with or without additional T-or B-cell depletion. 'Both' refers to patients with combined in vivo and in vitro manipulation.
Differences between disease categories
Patient characteristics. There were major differences in patient characteristics and treatment variables between the disease groups (Tables 1 and 2 ). Patients with juvenile idiopathic arthritis and autoimmune cytopenias were younger, and patients with systemic sclerosis and rheumatoid arthritis older than the median of 34 years. The proportion of female patients was higher in all but the immune thrombocytopenia group. The first autoimmune diseases to be treated in substantial numbers with HSCT were MS and hematologic diseases. Systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and juvenile idiopathic arthritis were increasingly treated in more recent years. Time intervals from diagnosis to transplant varied between disease groups. Median time from diagnosis to HSCT was 36 months (2-258 months) for systemic sclerosis, 59 months (2-235 months) for systemic lupus erythematosus, 72 months (15-250 months) for juvenile idiopathic arthritis, 81 months (3-344 months) for multiple sclerosis, 107 months (12-276 months) for immune thrombocytopenia and 113 months (24-287 months) for rheumatoid arthritis.
Treatment variables. Transplant techniques varied between all disease categories (Tables 2 and 3) . Peripheral blood was used as the stem cell source in about 90% of all patients and disease groups except for patients with juvenile idiopathic arthritis (45%), immune thrombocytopenia (20%) and systemic lupus erythematosus (18%) ( Table 2 ). In two-thirds, peripheral blood stem cells were mobilized with combined chemotherapy and growth factors. Growth factors alone were preferred primarily for patients with rheumatoid arthritis (60%) and immune thrombocytopenia (50%). Conditioning regimens were correlated with disease, but different conditioning regimens were used in all disease categories. BEAM was preferred for patients with multiple sclerosis (59%), and cyclophosphamide for patients with rheumatological disorders. There was heterogeneity in purging methods. No purging was used in as low as 4% of multiple sclerosis patients. In contrast, 91% of all juvenile idiopathic arthritis patients had combined in vitro and in vivo purging.
Outcome analysis
Outcomes studied were survival, transplant-related mortality, disease response and disease progression as defined previously. 8 All 473 patients were included in the survival analysis. Response analysis was restricted to the six major disease categories. Response assessment refers to best response at any time after HSCT and the time of assessment varied for the individual disease categories. Responses were classified as sustained, transient (fulfilled response definition but with a subsequent progression) or no response and defined for the individual disease categories as previously published:
for multiple sclerosis, stabilization or improvement of the Extended Disability Scoring System (EDSS) over the observation period, 12 for systemic sclerosis, an improvement in the modified Rodnan skin score over 25% from base line, 10 for rheumatoid arthritis, as an ACR (American College of Rheumatology) response of 50 sustained without reintroduction of disease-modifying antirheumatic drugs (DMARDs), 17 for juvenile idiopathic arthritis, as an increase of at least 30% in three out of six core set variables with a worsening of maximally 30% in no more than one of these parameters, 18 for systemic lupus erythematosus, as reduction of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) to o3 and a daily prednisone dose of 10 mg or less, 19 and for immune thrombocytopenia as normalization of the platelet count (4100 Â 10 9 /l) 20 Responses were reported by the transplant team as such, based on the above criteria. They could not be controlled by the writing committee and have to be regarded with some limitations.
Disease progression was defined as any worsening of these disease criteria after HSCT and include patients with no response and transient response.
Statistical methods
Groups and numerical variables were compared using the w 2 test. Transplant-related mortality, progression-free survival and overall survival were calculated using the Kaplan-Meier estimator. The 95% confidence interval was approximated using two times the standard error as calculated by the Greenwood formula. Multivariate analysis did focus on survival, response, disease progression and transplant-related mortality. It included age group (o20 y, 20-40 y, 440 y), sex, disease, time from diagnosis to transplant, mobilization, conditioning intensity, year of transplant and purging as variables as described above. Probability of survival, transplant-related mortality and response were calculated using Cox's regression analysis and disease progression by logistic regression models.
Results of multivariate analyses are expressed as relative risks (RR).
Results
Survival
At the time of the analysis (October 2003), 420 patients (89%) were alive and 53 patients (11%) had died: 31 (58% of deceased patients) of transplant-related causes and 22 (42% of deceased patients) of disease progression (Table 3) . Causes of transplanted-related mortality were infections (N ¼ 16; 50%), hemorrhage (N ¼ 4; 12.5%), cardiac toxicity (N ¼ 3), interstitial pneumonitis (N ¼ 2), veno-occlusive disease (N ¼ 2), suicide (N ¼ 1) and liver failure of unknown origin (N ¼ 1) or unknown causes (N ¼ 1). One patient with systemic lupus erythematosus and pancytopenia developed secondary leukaemia 2 years after HSCT and died. Survival was influenced by disease (Po0.005) (Figure 1a ; Table 4 ). It was highest in patients with rheumatoid arthritis and lower than average in systemic sclerosis, systemic lupus erythematosus and immune cytopenias. We failed to show an effect of purging on survival and mortality.
Transplant-related mortality
Transplant-related mortality at 3 years was 773%. It was associated with disease (Po0.005), year of transplant (P ¼ 0.04) and conditioning intensity (P ¼ 0.07) (Tables 3  and 4 ; Figures 1b and 2a) . Transplant-related mortality increased with increasing conditioning intensity stepwise from 373% in patients with low-intensity conditioning (RR1) to 1479% in patients with high-intensity conditioning, RR4.77 (1.02-22.1) (Figure 2a ; Table 4 ). Transplant-related mortality did decrease in all disease categories in more recent years, RR0.56 (0.32-0.97).
Response
In 299 of 370 evaluable patients (81%), response as defined above was observed. It remained sustained in 213 responders (71% of the responders). Of these, 71 patients (19%) failed to respond. Response and type of response differed between disease categories (Po0.0001) and were associated with age (P ¼ 0.06) and priming for stem cell collection (P ¼ 0.004). Response was more frequently observed in the young age group (RR1) compared to patients above age 40 years, RR0.29 (0.1-0.82), and more frequently in patients mobilized prior to HSCT with combined cyclophosphamide and growth factors, RR3.28 (1.57-6.83). Failure to respond was highest in patients with immune thrombocytopenia (Tables 4 and 5 ). Failure to respond might include patients with an aggravation of their disease after HSCT. There was no way to distinguish between these two groups in this retrospective analysis.
Disease progression
Disease progression despite initial response was 4976% at 3 years. It was associated with disease (Po0.0001) and intensity of the conditioning (Tables 4 and 5 ). It was 31717% at 3 years for patients with high-intensity conditioning (RR1) and increased stepwise with decreasing conditioning intensity and inversely to transplant-related mortality, to almost 7079% in patients with low-intensity conditioning, RR2.37 (1.074-5.11) (Figure 2b ; Table 4 ). There was a difference in disease progression in patients without purging methods in univariate (Table 5) analysis. Multivariate analyses failed to show an effect (Table 4) .
Discussion
The present data provide clear evidence that high-dose chemotherapy followed by autologous HSCT can arrest disease progression and induce stable remission in selected patients with severe autoimmune diseases. Response and toxicity differ from disease to disease and each disease has to be considered on its own. Data are obtained from a large international database with 110 participating institutions in 21 countries from Europe and Australasia. Teams used different transplant techniques, but did adhere in principle .The probability of TRM at 3 years was 373% in 133 patients receiving low-intensity conditioning regimens, 673% in 224 patients receiving intermediate-intensity conditioning regimens and 1479% in 72 patients receiving high-intensity conditioning regimens. Po0.04 for a global log-rank test. (b) Probability of disease activity (n ¼ 427). The probability of disease progression at 3 years was 7079% in 133 patients receiving low-intensity conditioning regimens, 4379% in 222 patients receiving intermediate-intensity conditioning regimens and 31717% in 72 patients receiving high-intensity conditioning regimens. P ¼ 0.0001 for a global log-rank test.
to a broadly stipulated concept statement of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). 8 Data are very heterogeneous in almost all aspects, in part incomplete, collected over a long observation period and have to be regarded with caution. Despite this heterogeneity, impact on outcome is observed in all disease categories and in all patient groups. These data extend preliminary results from early pilot and single disease focused studies. [10] [11] [12] [13] [14] [15] They confirm the concept of dose intensification as a therapeutic strategy. Increasing intensity reduces the risk of disease progression. In addition, interruption of inevitable disease progression has become possible. These data parallel the observations in lymphoid malignancies and multiple myeloma, that is, dose intensification and autologous HSCT reduce relapse and improve survival. [39] [40] [41] There is significant toxicity and there are limitations. Stem cell collection and autologous HSCT are associated with morbidity and mortality. Flares of the disease or lethal complications during mobilization have been reported. 9 Transplant-related mortality reached 773% in this report with a clear improvement over calendar time, presumably due to better patient selection and experience within the teams. 42 This overall transplant-related mortality is still high but comparable with that seen in autologous HSCT for hematological malignancies. [39] [40] [41] As in conventional indications for HSCT, risk of transplant-related mortality has to be compared with the risk of disease-related morbidity and mortality. Probability of death from disease progression at 3 years (974%) despite HSCT did exceed in this report the risk from transplant-related complications and possibly reflects the severity of the disease at the time of patient selection.
Main factors influencing transplant-related mortality in conventional indications are disease, stage of disease, age of patient, time from diagnosis to HSCT and year of transplant. In part, the same risk factors were identified. There was an association with age and disease stage within specified disease categories. A high EDSS score X6 (reflecting advanced disease in multiple sclerosis) or high pulmonary artery pressure (reflecting advanced disease in systemic sclerosis) were associated with poor outcome. 12, 35, 43 We did not attempt to define risk factors associated with specific causes of death, for example, hemorrhage, cardiac toxicity or veno-occlusive diseases. The numbers are too small, and the heterogeneity i.d. too large. Disease-specific analyses must provide these clues.
Selection of the conditioning regimen has been a matter of debate from the very beginning. 44 Results of this report provide more insight. High-intensity conditioning regimens were associated with higher risk of transplant-related mortality, but lower probability of disease progression. These novel findings indicate that impact of the procedure on disease outcome is not a chance finding. Sustained disease response was directly associated with survival. Patients with sustained response had a 100% survival at 3 years, and patients with no or transient response had a 20% probability to die from progressive disease within the same time interval. We cannot exclude that patients with response represent a selection of patients with inherent better prognosis. The fact that they were progressive before HSCT speaks for an active part of the procedure.
Autoimmune diseases represent a highly heterogeneous group of disorders and some disease-specific comments need to be added. In multiple sclerosis, flares of the disease have been observed during mobilization 45 during conditioning 12 and at the time of engraftment in the context of engraftment syndromes. 43 In systemic sclerosis, mortality appears to be correlated, especially with severe pulmonary artery hypertension. 10 However, successfully transplanted patients with moderate pulmonary hypertension may improve. Marked improvement of high skin scores and lung function has been observed. 46 Concepts of irreversible tissue damage during the fibrotic process need to be revised. In immune thrombocytopenia, bleeding remains a major concern and was associated with the death of two patients. 47 In systemic lupus erythematosus, initial improvement in all laboratory parameters have been observed in the majority of patients not necessarily correlated with autoantibody response; similar observations hold true for systemic sclerosis. In juvenile idiopathic arthritis, initial mortality was linked to a 'macrophage activation syndrome', better known as 'hemophagocytic lymphohistiocytosis'. 28 If observed and recognized as such early on, it can be treated with high-dose steroids.
Multiple mechanisms have been postulated to explain potential effects of autologous HSCT in the treatment of autoimmune diseases. 1, 5 Elimination of all autoreactive T or B cells has been advocated. Such considerations would also require elimination of T and B cells in the graft. The observation of similar response with or without graft manipulation and disease stabilization despite persistence of autoantibodies argues against this hypothesis. An association between purging and disease response or disease progression was suggested in univariate analysis, but could not be substantiated in multivariate analysis when other factors were taken into account. In contrast to the situation of tumor therapy, where no conceivable benefit could be derived from reinfusion of tumor cells, there are theoretical arguments against purging in patients with autoimmune diseases. In a rheumatoid arthritis HSCT trial, no clear benefit was demonstrated concerning disease relapse in manipulated vs unmanipulated grafts. 25 Any T-cell depletion or CD34 selection could eliminate autoreactive as well as regulatory T cells, and aggravate the autoimmune reaction. The role of graft manipulation remains open and needs to be addressed in controlled, disease-specific settings.
It remains open as to which is the best approach and best technology to be used, but some conclusions are possible. Standard technologies as used in the treatment of hematological malignancies can be applied. Peripheral blood remains the preferred source of stem cells. 44 Peripheral blood cells ensure more rapid reconstitution, can be collected easily in higher numbers than bone marrow cells and are easier to manipulate. Peripheral blood cells can be mobilized with or without cyclosphosphamide priming. Cyclophosphamide might provide higher cell numbers, give additional disease control and reduce the incidence of growth factor-induced disease flares. Concerning conditioning, there is no indication that disease-specific regimens are required. Conditioning intensity primarily impacts on outcome. Alternative approaches are being investigated for patients with severe autoimmune diseases, for example, the use of cyclophosphamide alone 48 or allogeneic HSCT. 49 Both are considered as more toxic approaches by the initial EBMT/EULAR statement. There is a prolonged period of aplasia with high-dose cyclophosphamide dose 50 and there is an inherent higher risk of transplant-related mortality with allogeneic HSCT. 49 A potential benefit from a graft-versus-autoimmune effect is still hypothetical. 3 In summary, the data suggest, despite their limitations, that high-dose chemotherapy and autologous HSCT can modify disease course in a substantial proportion of patients with severe autoimmune disorders. Risk factors for outcome can be defined. Prospective controlled studies are now warranted to define the value of autologous HSCT compared to nontransplant strategies and to establish longterm benefits. They have to be planned for each disease category. Such studies have started for patients with systemic sclerosis (www.astistrial.com), multiple sclerosis and rheumatoid arthritis. They are planned for patients with systemic lupus erythematosus or juvenile idiopathic arthritis and Crohn's disease. These trials are based on current results and should give an answer in the years to come. 
